(Q37153034)

18 August 2017

1 reference

title

Overweight and obesity: key components of cardiometabolic risk (English)

1 reference

18 August 2017

0 references

Louis J Aronne

1

1 reference

PubMed ID

18452840

18 August 2017

Kathy K Isoldi

series ordinal

2

1 reference

18 August 2017

1 January 2007

1 reference

18 August 2017

1 reference

18 August 2017

8

1 reference

18 August 2017

3

1 reference

18 August 2017

29-37

1 reference

Overweight and obesity in the United States: prevalence and trends, 1960-1994

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

The escalating pandemics of obesity and sedentary lifestyle. A call to action for clinicians

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Prevalence of overweight and obesity in the United States, 1999-2004

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Medical Consequences of Obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

The Epidemic of Obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

A potential decline in life expectancy in the United States in the 21st century

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Economic outcomes of the obese patient

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

National Medical Spending Attributable To Overweight And Obesity: How Much, And Who's Paying?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

The emerging science of body weight regulation and its impact on obesity treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Obesity and the role of adipose tissue in inflammation and metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Adiponectin: A novel adipokine linking adipocytes and vascular function

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Diabesity: An Inflammatory Metabolic Condition

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Adipokines: inflammation and the pleiotropic role of white adipose tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Obesity induces a phenotypic switch in adipose tissue macrophage polarization

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Disordered Fat Storage and Mobilization in the Pathogenesis of Insulin Resistance and Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Vascular function, insulin resistance and fatty acids

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Metabolic syndrome: a multiplex cardiovascular risk factor

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Treatment of obesity: need to focus on high risk abdominally obese patients

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Results of Expert Meetings: Obesity and Cardiovascular Disease. Introduction: Cardiologists should target obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

The behavioral approach to treating obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

To eat or not to eat - how the gut talks to the brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Self‐Regulation of Energy Intake in the Prevention and Treatment of Obesity: Is It Feasible?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Meta-analysis: pharmacologic treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Pharmacological approaches to weight reduction: therapeutic targets

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Randomized trial of lifestyle modification and pharmacotherapy for obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

The obesity epidemic: current and future pharmacological treatments

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Activation of the peripheral endocannabinoid system in human obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

1 reference

7 January 2021

Cannabinoid receptors as therapeutic targets.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2807%2980026-3

7 January 2021

10.1016/S1098-3597(07)80026-3

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18452840